PL3061771T3 - Nowy peptyd o czterech połączonych epitopach dla ctl - Google Patents

Nowy peptyd o czterech połączonych epitopach dla ctl

Info

Publication number
PL3061771T3
PL3061771T3 PL14856540T PL14856540T PL3061771T3 PL 3061771 T3 PL3061771 T3 PL 3061771T3 PL 14856540 T PL14856540 T PL 14856540T PL 14856540 T PL14856540 T PL 14856540T PL 3061771 T3 PL3061771 T3 PL 3061771T3
Authority
PL
Poland
Prior art keywords
novel
ctl epitope
peptide
joined
joined peptide
Prior art date
Application number
PL14856540T
Other languages
English (en)
Inventor
Satoshi Fukaya
Toshihiro OSADA
Hiroshi Wada
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3061771T3 publication Critical patent/PL3061771T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
PL14856540T 2013-10-21 2014-10-20 Nowy peptyd o czterech połączonych epitopach dla ctl PL3061771T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013218524 2013-10-21
JP2014155132 2014-07-30
PCT/JP2014/077807 WO2015060235A1 (ja) 2013-10-21 2014-10-20 新規ctlエピトープ4連結ペプチド
EP14856540.1A EP3061771B1 (en) 2013-10-21 2014-10-20 Novel four-ctl epitope-joined peptide

Publications (1)

Publication Number Publication Date
PL3061771T3 true PL3061771T3 (pl) 2020-10-19

Family

ID=52992831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14856540T PL3061771T3 (pl) 2013-10-21 2014-10-20 Nowy peptyd o czterech połączonych epitopach dla ctl

Country Status (19)

Country Link
US (1) US10137183B2 (pl)
EP (1) EP3061771B1 (pl)
JP (2) JP6211093B2 (pl)
KR (1) KR101913333B1 (pl)
CN (1) CN105658673B (pl)
AU (1) AU2014337643B2 (pl)
CA (1) CA2927817C (pl)
DK (1) DK3061771T3 (pl)
ES (1) ES2796301T3 (pl)
HU (1) HUE050164T2 (pl)
MX (1) MX377050B (pl)
MY (1) MY179119A (pl)
PH (1) PH12016500742B1 (pl)
PL (1) PL3061771T3 (pl)
PT (1) PT3061771T (pl)
RU (1) RU2636549C1 (pl)
SG (1) SG11201603165TA (pl)
TW (1) TWI651094B (pl)
WO (1) WO2015060235A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
EP3744847A4 (en) * 2018-01-22 2021-12-08 Japan as Represented by The Director-General of National Institute of Infectious Diseases SELECTIVE CD8 POSITIVE T CELL INDUCING VACCINE ANTIGEN
EP3815711A4 (en) * 2018-06-29 2022-08-10 Taiho Pharmaceutical Co., Ltd. ANTITUMORS AGENTS AND METHODS OF EVALUATION THEREOF
MY208035A (en) * 2018-11-02 2025-04-10 Taiho Pharmaceutical Co Ltd Emulsion formulation and method for preparing the same
EP4082563A4 (en) * 2019-12-26 2024-02-28 Taiho Pharmaceutical Co., Ltd. POST-OPERATIVE ADJUVANT THERAPY AGENT

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO1997032600A1 (fr) 1996-03-10 1997-09-12 Meiji Milk Products Co., Ltd. Agent immunotherapeutique a base peptidique pour le traitement des allergies
JP4138073B2 (ja) * 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
NZ510154A (en) 1998-08-28 2002-11-26 Sumitomo Pharma A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
US6667037B1 (en) 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE464383T1 (de) * 1999-08-05 2010-04-15 Greenpeptide Co Ltd Tumor antigen
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Mage-a12 항원성 펩티드 및 그의 용도
WO2001041741A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
WO2002010396A1 (en) * 2000-07-28 2002-02-07 Mogam Biotechnology Research Institute Gene expression system for mass production of hepatitis c viral rna-dependent rna polymerase and enzyme assay using fusion protein expressed therefrom
ATE389668T1 (de) 2000-07-31 2008-04-15 Greenpeptide Co Ltd Tumorantigen
JP4097178B2 (ja) * 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
EP1473564A4 (en) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
ATE441713T1 (de) 2002-09-27 2009-09-15 Dainippon Sumitomo Pharma Co Tumorantigenprotein und dessen verwendung
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4579581B2 (ja) * 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド
US7655751B2 (en) 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
EP1767541A4 (en) * 2004-05-26 2008-10-22 Greenpeptide Co Ltd HLA-A24 OR HLA-A2 BINDING PEPTIDE OF THE PARATHYROID HORMONE-RELATED PROTEIN
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2006188507A (ja) 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
JP5114403B2 (ja) * 2006-07-11 2013-01-09 株式会社グリーンペプタイド Hla−a3スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なsart3由来ペプチド
JP2008145715A (ja) * 2006-12-08 2008-06-26 Fujifilm Corp ポジ型感光性組成物、パターン形成方法、及び薄膜トランジスタアレイ基板
JP4972691B2 (ja) 2007-08-16 2012-07-11 株式会社グリーンペプタイド HLA−A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
ES2714200T3 (es) * 2007-09-18 2019-05-27 Brightpath Biotherapeutics Co Ltd Composición inductora de CTL
WO2012005161A1 (ja) 2010-07-07 2012-01-12 株式会社グリーンペプタイド がんペプチドワクチン
JP5911098B2 (ja) 2012-04-09 2016-04-27 国立研究開発法人情報通信研究機構 翻訳装置、およびプログラム
JP2014155132A (ja) 2013-02-13 2014-08-25 Murata Mfg Co Ltd 回路基板およびその製造方法
CN105008399B (zh) * 2013-03-08 2018-09-28 大鹏药品工业株式会社 新型的具有5个连接的ctl表位的肽

Also Published As

Publication number Publication date
EP3061771B1 (en) 2020-04-15
JP2017171678A (ja) 2017-09-28
PH12016500742B1 (en) 2020-10-23
SG11201603165TA (en) 2016-05-30
AU2014337643B2 (en) 2017-07-13
DK3061771T3 (da) 2020-07-13
US20160235828A1 (en) 2016-08-18
RU2636549C1 (ru) 2017-11-23
KR101913333B1 (ko) 2018-10-30
PH12016500742A1 (en) 2016-06-20
PT3061771T (pt) 2020-05-06
TWI651094B (zh) 2019-02-21
BR112016008254A2 (pt) 2017-09-26
MX2016004754A (es) 2016-07-22
ES2796301T3 (es) 2020-11-26
AU2014337643A1 (en) 2016-05-19
CA2927817C (en) 2019-02-26
JP6211093B2 (ja) 2017-10-11
TW201601749A (zh) 2016-01-16
MX377050B (es) 2025-03-07
EP3061771A1 (en) 2016-08-31
WO2015060235A1 (ja) 2015-04-30
EP3061771A4 (en) 2017-08-16
CA2927817A1 (en) 2015-04-30
MY179119A (en) 2020-10-28
US10137183B2 (en) 2018-11-27
HUE050164T2 (hu) 2020-12-28
KR20160055922A (ko) 2016-05-18
JPWO2015060235A1 (ja) 2017-03-09
CN105658673B (zh) 2019-07-26
CN105658673A (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
IL242005B (en) A peptide compound
SG11201602889TA (en) Novel polypeptides
GB201311475D0 (en) Polypeptides
ZA201600729B (en) Peptides
GB201308057D0 (en) Protein
ZA201504986B (en) Peptide
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
ZA201504987B (en) Peptide
GB201309421D0 (en) Polypeptides
GB201315130D0 (en) Peptides
PL2983690T3 (pl) Peptydy pochodzące od neuropeptydu Y
IL244956B (en) New peptide compositions
GB201401955D0 (en) Protein
PL3080276T3 (pl) Polipeptydy toksyczne dla owadów
GB201305465D0 (en) Novel peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201318941D0 (en) Novel polypeptides
GB201322749D0 (en) Cyclic peptide
GB201308193D0 (en) Peptide product
GB201308191D0 (en) Peptide product
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein
GB201317839D0 (en) Anti-Microbial peptides
GB201318182D0 (en) Inhibitor peptides